Detalhe da pesquisa
1.
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer.
N Engl J Med
; 387(3): 217-226, 2022 07 21.
Artigo
Inglês
| MEDLINE | ID: mdl-35857659
2.
Time-series blood cytokine profiles correlate with treatment responses in triple-negative breast cancer patients.
Br J Cancer
; 130(6): 1023-1035, 2024 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-38238427
3.
Changes in cell-free DNA after short-term palbociclib and fulvestrant treatment for advanced or metastatic hormone receptor-positive and human epidermal growth factor 2-negative breast cancer.
Breast Cancer Res Treat
; 203(2): 225-234, 2024 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-37875670
4.
A Century of Change: Unraveling the Impact of Socioeconomic/Historical Milestones on Age at Menarche and Other Female Reproductive Factors in Japan.
J Epidemiol
; 2024 Jan 06.
Artigo
Inglês
| MEDLINE | ID: mdl-38191181
5.
Olaparib efficacy in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer: Subgroup analyses from the phase III OlympiAD trial.
Int J Cancer
; 153(4): 803-814, 2023 08 15.
Artigo
Inglês
| MEDLINE | ID: mdl-36971103
6.
Patient characteristics, treatment patterns, and outcomes of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer patients prescribed cyclin-dependent kinase 4 and 6 inhibitors: large-scale data analysis using a Japanese claims database.
Breast Cancer Res Treat
; 197(2): 435-447, 2023 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-36414795
7.
Phase II trial of biweekly administration with eribulin after three cycles of induction therapy in hormone receptor-positive, HER2-negative metastatic breast cancer (JACCRO BC-03).
Breast Cancer Res Treat
; 201(3): 409-415, 2023 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-37480384
8.
Fulvestrant plus palbociclib in advanced or metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer after fulvestrant monotherapy: Japan Breast Cancer Research Group-M07 (FUTURE trial).
Breast Cancer Res Treat
; 199(2): 253-263, 2023 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-37000345
9.
Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapy.
Breast Cancer Res Treat
; 199(2): 231-241, 2023 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-36947277
10.
A risk-based subgroup analysis of the effect of adjuvant S-1 in estrogen receptor-positive, HER2-negative early breast cancer.
Breast Cancer Res Treat
; 202(3): 485-496, 2023 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-37676450
11.
Potential value of ctDNA monitoring in metastatic HR + /HER2 - breast cancer: longitudinal ctDNA analysis in the phase Ib MONALEESASIA trial.
BMC Med
; 21(1): 306, 2023 08 15.
Artigo
Inglês
| MEDLINE | ID: mdl-37580773
12.
Efficacy and exploratory biomarker analysis of entinostat plus exemestane in advanced or recurrent breast cancer: phase II randomized controlled trial.
Jpn J Clin Oncol
; 53(1): 4-15, 2023 Jan 06.
Artigo
Inglês
| MEDLINE | ID: mdl-36398439
13.
Retrospective study on the effectiveness of medroxyprogesterone acetate in the treatment of ER-positive/HER2-negative post-menopausal advanced breast cancer: an additional analysis of the JBCRG-C06 Safari study.
Jpn J Clin Oncol
; 53(3): 203-211, 2023 Mar 07.
Artigo
Inglês
| MEDLINE | ID: mdl-36484305
14.
Real-World Patient Characteristics, Treatment Patterns, and Outcomes of HR+, HER2- Early Breast Cancer Patients in Japan: An Analysis with National Database(NDB).
Gan To Kagaku Ryoho
; 50(12): 1283-1294, 2023 12.
Artigo
Inglês
| MEDLINE | ID: mdl-38247066
15.
Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial.
Lancet Oncol
; 23(5): 636-649, 2022 05.
Artigo
Inglês
| MEDLINE | ID: mdl-35405087
16.
Pertuzumab retreatment for HER2-positive advanced breast cancer: A randomized, open-label phase III study (PRECIOUS).
Cancer Sci
; 113(9): 3169-3179, 2022 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-35754298
17.
Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR.
BMC Med
; 20(1): 136, 2022 04 25.
Artigo
Inglês
| MEDLINE | ID: mdl-35462552
18.
Subgroup analysis of Japanese patients in a phase III randomized, controlled study of neoadjuvant atezolizumab or placebo, combined with nab-paclitaxel and anthracycline-based chemotherapy in early triple-negative breast cancer (IMpassion031).
Jpn J Clin Oncol
; 52(10): 1124-1133, 2022 Oct 06.
Artigo
Inglês
| MEDLINE | ID: mdl-35750038
19.
Factors associated with overall survival after recurrence in patients with ER-positive/HER2-negative postmenopausal breast cancer: an ad hoc analysis of the JBCRG-C06 Safari study.
Jpn J Clin Oncol
; 52(6): 545-553, 2022 May 31.
Artigo
Inglês
| MEDLINE | ID: mdl-35296894
20.
Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial.
Lancet Oncol
; 22(1): 74-84, 2021 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33387497